Novel Techniques May Provide ‘Incredible’ Benefits to Enhance CAR T-Cell Therapy

Multiple studies this year have placed renewed emphasis on efforts to identify ways to improve the effectiveness of CAR-T while minimizing toxicities. According to one preclinical study, led by Marco Ruella, MD, an assistant professor of Hematology-Oncology, deleting the CD5 gene from CAR T cells improved their expansion, durability and tumor-killing capabilities.